(IN BRIEF) Sanofi has agreed to acquire UK-based Vicebio for $1.15 billion upfront plus up to $450 million in milestones, with closing anticipated in Q4 2025. The deal adds an early-stage bivalent RSV/hMPV vaccine (VXB‑241, in Phase 1 for older adults) and … Read the full press release
Posted in Artificial Intelligence (AI), Business, Financial, France, Government, Healthcare, Industrial, Investment, Management, Marketing, News, Pharma & Biotech, Science, Security & Safety, Technology, United Kingdom
Tagged acquisition, AI-powered biopharma, Daniel Watterson, Emmanuel Hanon, fully liquid combination vaccines, Jean-François Toussaint, Keith Chappell, lower respiratory tract infections, Medicxi, Molecular Clamp technology, non-mRNA vaccine, Older Adults, partnership, Paul Young, pneumonia, prefilled syringes, regulatory approvals, respiratory vaccines pipeline, seasonal surges, Tags: Sanofi, UniQuest, University of Queensland, Vicebio
(IN BRIEF) Sanofi’s mRNA vaccine candidate for chlamydia has been granted fast track designation by the US FDA, reflecting its promising potential to address a significant public health issue. Designed to protect against primary and recurrent infections caused by Chlamydia … Read the full press release
Posted in France, Healthcare, Pharma & Biotech
Tagged asymptomatic infection, chlamydia, Chlamydia trachomatis, Fast Track Designation, Griffith University, immunogenicity, infertility, Jean-François Toussaint, mRNA vaccine candidate, pelvic inflammatory disease, phase 1/2 clinical study, pregnancy complications, public health need, Queensland Government, safety, Sanofi, Translational Science Hub, University of Queensland, US Food and Drug Administration
EuropaWire (EW) is the first truly pan-European and leading press release distribution and newswire service for Europe and the European Union working towards consolidating Europe’s voice on the global newswire and media scene. The newswire service comes with advanced submission forms, flexible pricing and PR budgeting, granular targeting, nearly uncapped reach across countries, markets, verticals, industries, audiences, languages, etc., translation and localisation for greater local PR impact, in-depth distribution reporting, metrics and insights including measured PR reach, reads, engagements, impact, etc., no cap on words, images and multimedia to go along with your release, among others. Your press releases will be seen among the releases of Europe’s biggest and most prominent companies, brands and institutions. Here you can learn more about EuropaWire’s mission, achievements, services, etc.
HOW TO GET STARTED?